Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC02210-CRHR1 readthrough represents a naturally occurring transcript formed between the neighboring genes CRHR1-IT1 (a noncoding RNA) and CRHR1 (corticotropin-releasing hormone receptor 1) by readthrough transcription on chromosome 17[2][8]. This readthrough RNA is reported as a protein-coding gene by some methods, potentially encoding a protein similar in sequence to CRHR1, but at least some transcripts appear noncoding or have undefined coding potential[2][3]. There is no experimental evidence for a unique, functional protein distinct from CRHR1 itself, and available data position LINC02210-CRHR1 within the context of noncoding RNA regulation — particularly with roles in cis-regulation of nearby genes, chromatin organization, and modulation of neuronal and stress-response pathways[1][9]. Disruption or altered expression in the 17q21.31 region, which contains this locus, has been associated with risk for neurodegenerative and neuropsychiatric diseases, but direct functional or therapeutic targeting data are lacking[1][9]. This locus is not a validated therapeutic target such as a typical receptor, enzyme, or transporter. Rather, it is a readthrough, potentially noncoding transcript or fusion product often studied for its possible regulatory or disease association roles, not for pharmacological intervention[1][2][3][8][9]. No drugs, clinical biomarkers, or mechanisms of action directly target LINC02210-CRHR1, and reported disease associations concern locus-level genetic variation rather than direct modulation or inhibition of the readthrough product[1][9]. Several names, including LINC02210, CRHR1-IT1, and C17ORF69, primarily appear in genomic/regulatory contexts or in discussions of chromosome 17q21.31 rearrangements[1][5][8]. For structured databases or clinical targeting purposes, LINC02210-CRHR1 readthrough is not considered a bona fide drug target; any entry should be flagged for manual review or possible exclusion from classic target lists.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LINC02210-CRHR1 readthrough (LINC02210-CRHR1).